These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 28356514)

  • 21. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Karaca Atabay E; Mecca C; Wang Q; Ambrogio C; Mota I; Prokoph N; Mura G; Martinengo C; Patrucco E; Leonardi G; Hossa J; Pich A; Mologni L; Gambacorti-Passerini C; Brugières L; Geoerger B; Turner SD; Voena C; Cheong TC; Chiarle R
    Blood; 2022 Feb; 139(5):717-731. PubMed ID: 34657149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.
    Wang H; Wei W; Zhang JP; Song Z; Li Y; Xiao W; Liu Y; Zeng MS; Petrus MN; Thomas CJ; Kadin ME; Nakagawa M; Waldmann TA; Yang Y
    Leukemia; 2021 Jul; 35(7):1976-1989. PubMed ID: 33184494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway.
    Chen X; Yang W; Deng X; Ye S; Xiao W
    Mol Vis; 2020; 26():517-529. PubMed ID: 32818015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
    Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
    Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
    Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
    Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
    Song L; Rawal B; Nemeth JA; Haura EB
    Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Anand M; Lai R; Gelebart P
    Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
    Zhang J; Wang P; Wu F; Li M; Sharon D; Ingham RJ; Hitt M; McMullen TP; Lai R
    Cell Signal; 2012 Apr; 24(4):852-8. PubMed ID: 22155737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
    Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
    Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
    Boi M; Zucca E; Inghirami G; Bertoni F
    Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
    Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
    Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
    Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
    Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
    Mastini C; Campisi M; Patrucco E; Mura G; Ferreira A; Costa C; Ambrogio C; Germena G; Martinengo C; Peola S; Mota I; Vissio E; Molinaro L; Arigoni M; Olivero M; Calogero R; Prokoph N; Tabbò F; Shoji B; Brugieres L; Geoerger B; Turner SD; Cuesta-Mateos C; D'Aliberti D; Mologni L; Piazza R; Gambacorti-Passerini C; Inghirami GG; Chiono V; Kamm RD; Hirsch E; Koch R; Weinstock DM; Aster JC; Voena C; Chiarle R
    Sci Transl Med; 2023 Jun; 15(702):eabo3826. PubMed ID: 37379367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
    Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
    Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.